U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H30N2O4
Molecular Weight 422.5167
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPTACOPAN

SMILES

CCO[C@H]1CCN(CC2=C(OC)C=C(C)C3=C2C=CN3)[C@@H](C1)C4=CC=C(C=C4)C(O)=O

InChI

InChIKey=RENRQMCACQEWFC-UGKGYDQZSA-N
InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H30N2O4
Molecular Weight 422.5167
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

2023
446
Substance Class Chemical
Created
by admin
on Wed Apr 02 00:18:59 GMT 2025
Edited
by admin
on Wed Apr 02 00:18:59 GMT 2025
Record UNII
8E05T07Z6W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
iptacopan [INN]
Preferred Name English
IPTACOPAN
INN   USAN  
Official Name English
IPTACOPAN [USAN]
Common Name English
LNP-023
Code English
NVP-LNP023
Code English
LNP023
Code English
NVP-LNP023-NX
Code English
Iptacopan [WHO-DD]
Common Name English
BENZOIC ACID, 4-((2S,4S)-4-ETHOXY-1-((5-METHOXY-7-METHYL-1H-INDOL-4-YL)METHYL)-2-PIPERIDINYL)-
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 692819
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C156691
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
PUBCHEM
90467622
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
DAILYMED
8E05T07Z6W
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
WIKIPEDIA
Iptacopan
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
SMS_ID
300000023892
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
INN
11259
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
FDA UNII
8E05T07Z6W
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
CAS
1644670-37-0
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
USAN
JK-156
Created by admin on Wed Apr 02 00:18:59 GMT 2025 , Edited by admin on Wed Apr 02 00:18:59 GMT 2025
PRIMARY
Related Record Type Details
OAT-3
TRANSPORTER -> NON-SUBSTRATE
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
OAT-1
TRANSPORTER -> NON-SUBSTRATE
Structure of IPTACOPAN
EXCRETED UNCHANGED
FECAL
OAT-2
TRANSPORTER -> NON-SUBSTRATE
Structure of IPTACOPAN HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of IPTACOPAN
EXCRETED UNCHANGED
URINE
OCT-2
TRANSPORTER -> NON-SUBSTRATE
COMPLEMENT FACTOR B
TARGET -> INHIBITOR
Using 6% human sera. Zymosan induced MAC deposition (Alternative pathway for complement activation.)
IC50
COMPLEMENT FACTOR B
TARGET -> INHIBITOR
Kd
OATP1B1
TRANSPORTER -> SUBSTRATE
COMPLEMENT FACTOR B
TARGET -> INHIBITOR
Zymosan induced MAC deposition (Alternative pathway for complement activation.) In 50% serum.
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
over the concentration range of 100 ng/mL to 5000 ng/mL, iptacopan was approximately 99% to 75% protein bound. Binding of iptacopan to plasma proteins is concentration dependent possibly due to saturable binding to drug target Factor B.
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
COMPLEMENT FACTOR B
TARGET -> INHIBITOR
Activity was assessed in a time-resolved fluorescence resonance energy transfer (TR-FRET) based competitive binding assay using the catalytic domain of human factor B (FB).
IC50
Structure of IPTACOPAN HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
MAJOR
MRP-2
TRANSPORTER -> SUBSTRATE
OATP-8
TRANSPORTER -> SUBSTRATE
Related Record Type Details
Structure of MHT-297
METABOLITE -> PARENT
PLASMA
Structure of JKH-504
METABOLITE LESS ACTIVE -> PARENT
Structure of YJA-654
METABOLITE -> PARENT
Structure of OHD-443
METABOLITE -> PARENT
PLASMA; URINE
Structure of OH-J739
METABOLITE -> PARENT
PLASMA
Related Record Type Details
Structure of IPTACOPAN
ACTIVE MOIETY
Inhibits the alternative complement pathway by binding to the Bb domain of Factor B, which reduces formation of the Bb-containing C3 convertase. Reduction in C3 convertase activity is anticipated to reduce the degree of both intravascular and extravascular hemolysis in certain complement-driven disorders such as PNH.
Structure of IPTACOPAN
ACTIVE MOIETY
Inhibits the alternative complement pathway by binding to the Bb domain of Factor B, which reduces formation of the Bb-containing C3 convertase. Reduction in C3 convertase activity is anticipated to reduce the degree of both intravascular and extravascular hemolysis in certain complement-driven disorders such as PNH.
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
BRAIN/PLASMA RATIO PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966